Train-of-four to monitor neuromuscular blockade?

Chest

Volumn 126, Issue 4, 2004, Pages 1018-1022

  Sessler, Curtis N ^a,b  

^a VA Cmw University Health System ^*  (United States)

^b VA Cmw University Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT;

DRUG MONITORING; EDITORIAL; HUMAN; MUSCLE RELAXATION; MYOPATHY; NEUROMUSCULAR BLOCKING; PATIENT MONITORING; POLYNEUROPATHY; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 6344226438     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.4.1018     Document Type: Editorial

References (39)

1. Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 30:142-156
2. Gehr LC, Sessler CN. Neuromuscular blockade in the Intensive Care Unit. Semin Respir Crit Care Med 2001; 22:175-188
3. Deem S, Lee CM, Curtis JR. Acquired neuromuscular disorders in the intensive care unit. Am J Respir Crit Care Med 2003; 168:735-739
4. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288:2859-2867
5. Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31:1012-1016
6. Rudis MI, Guslits BJ, Peterson EL, et al. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996; 24:1749-1756
7. Sladen RN. Neuromuscular blocking agents in the intensive care unit: a two-edged sword. Crit Care Med 1995; 23:423-428
8. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary: Society of Critical Care Medicine. Crit Care Med 1995; 23:1601-1605
9. Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:575-583
10. Strange C, Vaughan L, Franklin C, et al. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med 1997; 156:1556-1561
11. Gainnier M, Roch A, Forel JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004; 32:113-119
12. Appadu BL, Greiff JM, Thompson JP. Postal survey on the long-term use of neuromuscular block in the intensive care. Intensive Care Med 1996; 22:862-866
13. Hansen-Flaschen JH, Brazinsky S, Basile C, et al. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey. JAMA 1991; 266:2870-2875
14. Kleinpell R, Bedrosian C, McCormick L, et al. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care 1996; 5:449-454
15. Tavernier B, Rannou JJ, Vallet B. Peripheral nerve stimulation and clinical assessment for dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1998; 26:804-805
16. Mascia MF, Koch M, Medicis JJ. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med 2000; 28:2300-2306
17. Frankel H, Jeng J, Tilly E, et al. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg 1996; 62:503-506
18. Zarowitz BJ, Rudis MI, Lai K, et al. Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy 1997; 17:327-332
19. Pearson AJ, Harper NJ, Pollard BJ. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Intensive Care Med 1996; 22:694-698
20. Newman PJ, Quinn AC, Grounds RM, et al. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med 1997; 25:1139-1142
21. Prielipp RC, Coursin DB, Scuderi PE, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 1995; 81:3-12
22. Lagneau F, D'Honneur G, Plaud B, et al. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med 2002; 28:1735-1741
23. Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327:524-528
24. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22:884-893
25. Hansen-Flaschen J, Cowen J, Raps EC. Neuromuscular blockade in the intensive care unit: more than we bargained for. Am Rev Respir Dis 1993; 147:234-236
26. Caldwell JE, Szenohradszky J, Segredo V, et al. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther 1994; 270:1216-1222
27. Segredo V, Caldwell JE, Wright PM, et al. Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients? Br J Anaesth 1998; 80:715-719
28. Leatherman JW, Fluegel WL, David WS, et al. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996; 153:1686-1690
29. David WS, Roehr CL, Leatherman JW. EMG findings in acute myopathy with status asthmaticus, steroids and paralytics: clinical and electrophysiologic correlation. Electromyogr Clin Neurophysiol 1998; 38:371-376
30. Fischer JR, Baer RK. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Ann Pharmacother 1996; 30:1437-1445
31. Douglass JA, Tuxen DV, Horne M, et al. Myopathy in severe asthma. Am Rev Respir Dis 1992; 146:517-519
32. Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000; 28:34-45
33. Giostra E, Magistris MR, Pizzolato G, et al. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide: occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination. Chest 1994; 106:210-220
34. Davis NA, Rodgers JE, Gonzalez ER, et al. Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med 1998; 26:1290-1292
35. Marik PE. Doxacurium-corticosteroid acute myopathy: another piece to the puzzle. Crit Care Med 1996; 24:1266-1267
36. Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother 1996; 30:165-172
37. Tschida SJ, Hoey LL, Mather D, et al. Train-of-four: to use or not to use. Pharmacotherapy 1995; 15:546-550
38. Murray MJ. Monitoring of peripheral nerve stimulation versus standard clinical assessment for dosing of neuromuscular blocking agents. Crit Care Med 1997; 25:561-562
39. Lagneau F, Benayoun L, Plaud B, et al. The interpretation of train-of-four monitoring in intensive care: what about the muscle site and the current intensity? Intensive Care Med 2001; 27:1058-1063